Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
Key Highlights
- ➤Evogene targets acute GVHD with potential first-in-class small-molecule therapy
- ➤aGVHD affects approximately 30%–40% of transplant recipients
- ➤Steroid-refractory aGVHD mortality can reach 50%
- ➤ChemPass AI™ explored more than 110 billion molecules
- ➤Evogene aims to advance lead candidates toward IND-enabling studies
Expert Statements
Robert Zeiser, Head of Tumor Immunology at University Medical Center Freiburg
“Our research identified a specific signaling pathway that is highly overactive and plays a central role in driving severe inflammation in steroid-refractory acute GVHD.”
Robert Zeiser, Head of Tumor Immunology at University Medical Center Freiburg
“Targeting this pathway offers a compelling therapeutic approach. Evogene's computationally designed lead molecules are intended to provide specificity and potency against these pathological mechanisms, establishing a strong data-driven basis for a next-generation therapeutic strategy.”
Corey Cutler, MD, MPH, Director of the Adult Stem Cell Transplantation Program at Dana-Farber Cancer Institute
“Acute GVHD remains an area of significant unmet clinical need, with ruxolitinib the only approved second-line therapy.”
Corey Cutler, MD, MPH, Director of the Adult Stem Cell Transplantation Program at Dana-Farber Cancer Institute
“Patients who fail initial steroid treatment face poor prognoses. A targeted, well-tolerated small-molecule inhibitor that modulates this critical pathway of immune dysregulation has the potential to become a cornerstone of treatment and significantly improve patient outcomes.”
Gabi Tarcic, Chief Development Officer of Evogene
“The launch of our aGVHD program marks the execution of Evogene's strategic commitment to advancing proprietary, internally developed therapeutic assets.”
Gabi Tarcic, Chief Development Officer of Evogene
“By applying our ChemPass AI™ platform to this challenging target biology, we generated novel molecular candidates with optimized properties in just months.”
Gabi Tarcic, Chief Development Officer of Evogene
“This program demonstrates the potential of our generative AI technology to accelerate discovery while producing diverse chemical scaffolds optimized for drug development.”
Gabi Tarcic, Chief Development Officer of Evogene
“We look forward to advancing these lead candidates toward IND-enabling studies.”
Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program PR Newswire
Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory Patients
Get started
Create a free account to read the full story.